Kommentar zu „Prognostische Faktoren bei fortgeschrittenen Kopf-Hals-Tumoren”

• Literatur

• 1 Burtness B, Harrington KJ, Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.. Lancet 2019; 394: 1915-1928
• 2 Schubert P, Rutzner S, Eckstein M. et al. Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors.. Front Oncol 2020; 10: 576643